Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Naive Metastatic Lung Adenocarcinoma.

ABSTRACT:

Background

To compare the testing costs and testing turnaround times of tissue-first, plasma-first, and complementary next-generation sequencing (NGS) approaches in patients with treatment-naïve metastatic lung adenocarcinoma.

Materials and methods

We developed a decision tree model to compare three different approaches. Patients were entered into the model upon cancer diagnosis and those with both insufficient tissue specimens and negative liquid-based NGS were subjected to tissue re-biopsy. Actionable gene alterations with the U.S. Food and Drug Administration (FDA)-approved therapies included epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) gene rearrangement, ROS proto-oncogene 1 (ROS1) rearrangement, B-Raf

SUBMITTER: Yang SC 

PROVIDER: S-EPMC9163561 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature